Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPI-386 Nasal Gel for Motion Sickness Prevention
NCT04272255Phase 3Unknown
- Sponsor
- Defender Pharmaceuticals
- Start
- Apr 2019
- Primary completion
- Jun 2020
- Modality
- Placebo
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of placebo gel (Naval Aeromedical Research Unit, Dayton) in motion sickness (3 arms), sponsored by Defender Pharmaceuticals. Primary endpoints: Efficacy of DPI-386 Nasal Gel at 3 days and Safety of DPI-386 Nasal Gel in terms of cognitive effects at 24 hours. Status: unknown.
02
Drugs
placebo gel (Naval Aeromedical Research Unit, Dayton)
03
Conditions
motion sickness
Beyond the preview
Go deeper on NCT04272255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04272255.